-
-
-
-
-
-
-
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025
-
-
-
-
-
-
-
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025
-
-
-
-
-
-
-
Fulcrum Therapeutics Announces Recent Business Highlights and Financial ResultsĀ for Third Quarter 2024
-
-
-
-
-
-
-
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
-
-
-
-
-
-
-
Fulcrum Therapeutics to Host Third Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023, at 8:00 a.m. ET
-
-
-
-
-
-
-
FULCRUM THERAPEUTICS, INC. (NASDAQ: FULC) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit
-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fulcrum, adidas, and Spirit and Encourages Investors to Contact the Firm
-
1,199,626 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

